Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Overview of attention for article published in Lancet Oncology, February 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 6 news outlets
blogs: 3 blogs
policy: 2 policy sources
twitter: 27 X users

patent: 87 patents
facebook: 5 Facebook pages
f1000: 1 research highlight platform
guideline: 3 clinical guideline sources

Readers on

mendeley: 882 Mendeley

So far, Altmetric has seen 87 patents that reference this research output.

Tumor cell-derived exosomes and method of treating colorectal cancer

Grant US-12728156-B2

United States of America

08 Sep 2026

Treatment of urothelial and kidney cancers by use of endothelin B receptor antagonists

Grant US-12728122-B2

United States of America

08 Sep 2026

Formulations and doses of pegylated uricase

Grant US-12553041-B2

United States of America

17 Feb 2026

Methods and compositions for treatment of Endothelin B receptor expressing tumors

Grant US-12533390-B2

United States of America

27 Jan 2026

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 83 additional patents.